Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-19T09:05:57.996Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychiatric symptoms and cognitive dysfunction caused by Epstein–Barr virus-induced encephalitis

Published online by Cambridge University Press:  16 April 2020

Joachim Behr M.D. ,
Martin Schaefer M.D. ,
Eckhard Littmann Ph.D. ,
Randolf Klingebiel M.D.  and
Andreas Heinz M.D.
Joachim Behr M.D.*
Affiliation:
Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr. 20/21, 10117Berlin, Germany Neuroscience Research Center, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr. 20/21, 10117Berlin, Germany
Martin Schaefer M.D.
Affiliation:
Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr. 20/21, 10117Berlin, Germany
Eckhard Littmann Ph.D.
Affiliation:
Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr. 20/21, 10117Berlin, Germany
Randolf Klingebiel M.D.
Affiliation:
Department of Radiology, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr. 20/21, 10117Berlin, Germany
Andreas Heinz M.D.
Affiliation:
Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr. 20/21, 10117Berlin, Germany
*
*Corresponding author. Tel.: +49 30 450 539031; fax: +49 30 450 539941. E-mail address: [email protected] (J. Behr).
Get access

Abstract

Epstein-Barr virus (EBV) encephalitis is rare and shows a wide range of clinical manifestations. We report an immunocompromised patient with EBV encephalitis diagnosed by EBV-specific PCR and antibody testing in the cerebrospinal fluid who presented with psychiatric symptoms and cognitive dysfunction in the absence of any neurological impairments or infectious signs. Clinical recovery and clearance of cerebrospinal fluid EBV DNA appeared following ganciclovir treatment within 6 weeks.

Keywords

Epstein–Barr virusPsychiatric symptomsCognitive dysfunctionEncephalitisBone marrow transplantationGanciclovir
Type
Case-report
Information
European Psychiatry , Volume 21 , Issue 8 , December 2006 , pp. 521 - 522
Copyright
Copyright © Elsevier Masson SAS 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bray, P.F., Culp, K.W., McFarlin, D.E., Panitch, H.S., Torkelson, R.D., Schlight, J.P.Demyelinating disease after neurologically complicated primary Epstein–Barr virus infection Neurology 1992; 42:278–282.CrossRefGoogle ScholarPubMed
Marks, J.E., Baglan, R.J., Prassad, S.C., Blank, W.F.Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume Int. J. Radiat. Oncol. Biol. Phys. 1981; 7:243–252.CrossRefGoogle ScholarPubMed
Morris, J.C., Mohs, R.C., Rogers, H., Fillenbaum, G., Heyman, A.Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease Psychopharmacol. Bull. 1988; 24:641–652.Google ScholarPubMed
Padovan, C.S., Bise, K., Hahn, J., Sostak, P., Holler, E., Kolb, H.J.et al.Angiitis of the central nervous system after allogeneic bone marrow transplantation? Stroke 1999; 30:1651–1656.CrossRefGoogle ScholarPubMed
Sostak, P., Padovan, C.S., Yousry, T.A., Ledderose, G., Kolb, H.J., Straube, A.Prospective evaluation of neurological complications after allogeneic bone marrow transplantation Neurology 2003; 60:842–848.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.